CTLA4 and melanoma: Consistently, combination therapy of anti–CTLA-4 and anti–PDL-1 mAbs plus an anticancer vaccine resulted in a significant increase in IFN-γ production by both CD4+ and CD8+ cells, which correlated with higher rates of melanoma tumor rejection (47).